Enzymatica
1,85 SEK -2,12%Vær den første som følger denne virksomhed
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Omsætning
50,9 mio.
EBIT %
-94,42 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
ENZY
Daglig lav / høj pris
1,85 / 1,9
SEK
Markedsværdi
449,06 mio. SEK
Aktieomsætning
45,66 t SEK
Volumen
25 t
Finanskalender
Delårsrapport
07.11.2024
Årsrapport
18.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Mats Andersson, privat och genom bolag | 24,2 % | 24,2 % |
Roosgruppen AB | 13,6 % | 13,6 % |
Björn Algkvist, genom Fibonacci Asset Management | 11,5 % | 11,5 % |
Bengt Baron, privat och genom bolag | 4,4 % | 4,4 % |
Tom Stendahl | 2,8 % | 2,8 % |
Jan Olof Backman, genom Backman Invest AB | 2,8 % | 2,8 % |
Nordnet Pensionsförsäkring AB | 2,6 % | 2,6 % |
Peter Bevelin, genom Aktiebolaget Possessor | 2,5 % | 2,5 % |
Carl och Claes Kinell, privat och genom Muirfield Invest AB | 2,5 % | 2,5 % |
Ágústa Gudmundsdottir, privat och genom bolag | 2,1 % | 2,1 % |
ViserAlle indholdstyper
Enzymatica AB: BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms
Enzymatica AB: Enzymatica publishes supplementary prospectus
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools